Navigation Links
Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013
Date:11/30/2009

WALTHAM, Mass., Nov. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the hepatitis C virus drug market in Russia will grow nine percent annually over the 2008 - 2013 study period, reaching $327 million by 2013. This growth will be driven mainly by increased government spending on healthcare and increased use of more-expensive therapies like pegylated interferons [peg-IFNs] (i.e., Roche's Pegasys and Schering-Plough's PegIntron) instead of conventional interferons (i.e., Roche's Roferon and Schering-Plough's Intron A).

As Russia's gross domestic product (GDP) per capita continues to grow, both government and private healthcare spending is expected to increase as well. In 2007, the International Monetary Fund reported government spending on healthcare was only about 3.5 percent of Russia's GDP, but the World Bank and other sources expect this number to increase to 5.5 percent of Russia's GDP by 2013.

The new Emerging Markets report entitled Hepatitis C Virus in Russia also finds that Pegasys and PegIntron will benefit from market growth in Russia. Sales of these two agents will account for 77 percent of the total hepatitis C virus drug market in 2013, an increase from 68 percent in 2008.

"In Russia, Pegasys and PegIntron currently capture a relatively small patient share but have growth potential because physicians and patients perceive them to be more effective and safer than conventional interferons," stated Alexandra Makarova, M.D., Ph.D., analyst at Decision Resources.

The new report is part of an expansion of the Emerging Markets report series to cover Russia. The series contains primary research of physicians and epidemiology study in key pharmaceutical markets of Russia -- Moscow, Saint Petersburg and Novosibirsk.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:



Gisselle Morales                             Elizabeth Marshall
Decision Resources                           Decision Resources, Inc.
781-296-2691                                 781-296-2563
gmorales@dresources.com                      emarshall@dresources.com


SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
3. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
4. Noninvasive Breath Test Predicts Survival in Patients with Viral Hepatitis
5. Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C Treatment
6. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
7. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
10. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Clinical Update - Debio 025 in Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... India , April 29, 2016 ... Pipeline Review, H1 2016" market research report that ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:4/29/2016)... , April 29, 2016 Glycotope ... expertise, today announces the appointment of Dr. Alfredo ... Zurlo is an oncologist with many years clinical experience ... biotechnology industries. His last role was at Mologen AG ... the Executive Board. Previously Dr. Zurlo held various positions ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 30, 2016 , ... Mercy College is expanding its Graduate Business Programs to ... expanding due to high demand: Master of Business Administration (MBA), Master of Organizational Leadership ... , School of Business Graduate Program Chair Dr. Ray Manganelli said: “We believe ...
(Date:4/29/2016)... ... 2016 , ... Memorial Healthcare System Graduate Medical Education ... that it has received accreditation for its residency program on Physical Medicine and ... Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation allows the ...
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... VA (PRWEB) , ... April 29, 2016 , ... ... with student loans more flexibility in repaying their loans, more information about their ... a time when total outstanding student loan debt, including federal and private loans, ...
(Date:4/29/2016)... Fla. (PRWEB) , ... April 29, 2016 , ... ... Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have better ... is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to ...
Breaking Medicine News(10 mins):